SEC Form 4 · accession 0001209191-17-059637
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Parini
Officer — EVP, CL&AO
Period of report
Nov 3, 2017
Accepted (ET)
Nov 7, 2017 · 5:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 3, 2017 | M | 2,330 | $86.52 | A | 31,139 | D | |
| Common Stock | Nov 3, 2017 | S | 2,330 | $149.50 | D | 28,809 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $86.52 | Nov 3, 2017 | M | 2,330 | D | — | Feb 2, 2027 | Common Stock | 2,330 | 30,289 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1.
- F2The option vests in 16 quarterly installments from 2/3/2017.